CBL 514
Alternative Names: CBL-514Latest Information Update: 17 Sep 2024
At a glance
- Originator Caliway Biopharmaceuticals Australia
- Class Obesity therapies; Skin disorder therapies; Small molecules
- Mechanism of Action Apoptosis stimulants; Lipolysis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Adiposis dolorosa
- Phase II Cellulite; Obesity; Subcutaneous fat disorders
Most Recent Events
- 03 Sep 2024 Caliway Biopharmaceuticals initiates a phase II trial for Adiposis dolorosa in USA (SC) (NCT06303570)
- 03 Sep 2024 Phase-III clinical trials in Adiposis dolorosa in USA (SC)
- 03 Sep 2024 Caliway Biopharmaceuticals intends to submit IND application for a phase III pivotal trial for Adiposis dolorosa